Chen WQ, Zheng RS, Zhang SW, Zou XN, Zhao P, He J. Lung cancer incidence and mortality in China. Thorac Cancer. 2013;4:102–8.
Jemal A, Siegel R, Xu J, Ward E. Cancer statistic. CA Cancer J Clin. 2010;60:277–300.
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics 2014. CA Cancer J Clin. 2014;64:9–29.
DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics. CA Cancer J Clin. 2014;64(4):252–71.
Pastorino U. Lung cancer screening. Br J Cancer. 2010;102:1681–6.
Travis WD. Pathology of lung cancer. Clin Chest Med. 2011;32:669–92.
Liu XH, Lu KH, Wang KM, Sun M, Zhang EB, Yang JS, et al. MicroRNA-196a promotes non-small cell lung cancer cell proliferation and invasion through targeting HOXA5. BMC Cancer. 2012;12:348.
Gutschner T, Hammerle M, Eissmann M, Hsu J, Kim Y, Hung G, et al. The non-coding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 2013;73(3):1180–9.
Van Roosbroeck K, Pollet J, Calin GA. MiRNAs and long noncoding RNAs as biomarkers in human diseases. Expert Rev Mol Diagn. 2013;13:183–204.
International Human Genome Sequencing C. Finishing the euchromatic sequence of the human genome. Nature. 2004;431:931–45.
Mattick JS, Makunin IV. Non-coding RNA. Hum Mol Genet. 2006;15(Spec No 1):R17–29.
Eddy SR. Non-coding RNA genes and the modern RNA world. Nat Rev Genet. 2001;2:919–29.
Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, et al. Long non-coding RNA HOTAIR reprogramschromatin state to promote cancer metastasis. Nature. 2010;464(7291):1071–6.
Loewer S, Cabili MN, Guttman M, Loh YH, Thomas K, Park IH, et al. Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells. Nat Genet. 2010;42(12):1113–7.
Wang J, Liu X, Wu H, Ni P, Gu Z, Qiao Y, et al. CREB upregulates long non-coding RNA, HULC expression through interaction withmicroRNA-372 in liver cancer. Nucleic Acids Res. 2010;38(16):5366–83.
Khaitan D, Dinger ME, Mazar J, Crawford J, Smith MA, Mattick JS, et al. The melanoma-upregulated long noncoding RNA SPRY4-IT1 modulates apoptosis and invasion. Cancer Res. 2011;71(11):3852–62.
Yang F, Zhang L, Huo XS, Yuan JH, Xu D, Yuan SX, et al. Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans. Hepatology. 2011;54(5):1679–89.
Cui Z, Ren S, Lu J, Wang F, Xu W, Sun Y, et al. The prostate cancer-up-regulated long noncoding RNA PlncRNA-1 modulates apoptosis and proliferation through reciprocal regulation of androgen receptor. Urol Oncol. 2013;31(7):1117–23.
Wang Y, Chen W, Yang C, Wu W, Wu S, Qin X, et al. Long non-coding RNA UCA1a (CUDR) promotes proliferation and tumorigenesis of bladder cancer. Int J Oncol. 2012;41(1):276–84.
Jin G, Sun J, Isaacs SD, Wiley KE, Kim ST, Chu LW, et al. Human polymorphisms at long non-coding RNAs (lncRNAs) and association with prostate cancer risk. Carcinogenesis. 2011;32(11):1655–9.
Geng YJ, Xie SL, Li Q, Ma J, Wang GY. Large intervening non-coding RNA HOTAIR is associated with hepatocellular carcinoma progression. J IntMed Res. 2011;39(6):2119–28.
Li X, Jiang XY, Ge J, Wang J, Chen GJ, Xu L, et al. Aberrantly expressed lncRNAs in primary varicose great saphenous veins. PLOS ONE. 2014;9:e86156.
Dong R, Jia D, Xue P, Cui X, Li K, Zheng S, et al. Genome-wide analysis of long noncoding RNA (lncRNA) expression in hepatoblastoma tissues. PLOS ONE. 2014;9:e85599.
Crea F, Watahiki A, Quagliata L, Xue H, Pikor L, Parolia A, et al. Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer. Oncotarget. 2014;5:764–74.
Ren S, Wang F, Shen J, Sun Y, Xu W, Lu J, et al. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer. Eur J Cancer. 2013;49:2949–59.
Cao WJ, Wu HL, He BS, Zhang YS, Zhang ZY. Analysis of long non-coding RNA expression profiles in gastric cancer. World J Gastroenterol. 2013;19:3658–64.
Jiang YJ, Bikle DD. LncRNA: a new player in 1α, 25 (OH) 2 vitamin D3/VDR protection against skin cancer formation. Exp Dermatol. 2014;23:147–50.
Kim K, Jutooru I, Chadalapaka G, Johnson G, Frank J, Burghardt R, et al. HOTAIR is a negative prognostic factor and exhibits prooncogenic activity in pancreatic cancer. Oncogene. 2013;32(13):1616–25.
Ji P, Diederichs S, Wang W, Boing S, Metzger R, Schneider PM, et al. MALAT-1, a novel noncoding RNA, and thymosin beta 4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene. 2003;22(39):8031–41.
Takahashi Y, Sawada G, Kurashige J, Uchi R, Matsumura T, Ueo H, et al. Amplification of PVT-1 is involved in poor prognosis via apoptosis inhibition in colorectal cancers. Br J Cancer. 2014;110:164–71.
Lin R, Maeda S, Liu C, Karin M, Edgington TS. A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas. Oncogene. 2007;26(6):851–8.
Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136(4):629–41.
Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea Morales D, et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci U S A. 2009;106(28):11667–72.
Perez DS, Hoage TR, Pritchett JR, Ducharme SAL, Halling ML, Ganapathiraju SC, et al. Abundantly expressed non-coding transcripts are altered in cancer. Hum Mol Genet. 2008;17:642–55.
Guttman M, Donaghey J, Carey BW, Garber M, Grenier JK, Munson G, et al. lncRNAs act in the circuitry controlling pluripotency and differentiation. Nature. 2011;477:295–300.
Yuan SX, Yang F, Yang Y, Tao QF, Zhang J, Huang G, et al. Long non-coding RNA-MVIH promotes angiogenesis and serves as a predictor for HCC patients’ poor recurrence-free survival after hepatectomy. Hepatology. 2012;56(6):2231–41.
Spizzo R, Almeida MI, Colombatti A, Calin GA. Long non-coding RNAs and cancer: a new frontier of translational research? Oncogene. 2012;31:4577–87.
Hara F, Samuel S, Liu J, Rosen D, Langley RR, Naora H. A homeobox gene related to Drosophila distal-less promotes ovarian tumorigenicity by inducing expression of vascular endothelial growth factor and fibroblast growth factor-2. Am J Pathol. 2007;170:1594–606.
Man YG, Fu SW, Schwartz A, Pinzone JJ, Simmens SJ, Berg PE. Expression of BP1, a novel homeobox gene, correlates with breast cancer progression and invasion. Breast Cancer Res Treat. 2005;90:241–7.
Tan Y, Timakhov RA, Rao M, Altomare DA, Xu J, Liu Z, et al. A novel recurrent chromosomal inversion implicates the homeobox gene Dlx5 in T-cell lymphomas from Lck-Akt2 transgenic mice. Cancer Res. 2008;68:1296–302.
Tan Y, Cheung M, Pei J, Menges CW, Godwin AK, Testa JR. Upregulation of DLX5 promotes ovarian cancer cell proliferation by enhancing IRS-2-AKT signaling. Cancer Res. 2010;70:9197–206.
Kato T, Sato N, Takano A, Miyamoto M, Nishimura H, Tsuchiya E, et al. Activation of placenta-specific transcription factor distal-less homeobox 5 predicts clinical outcome in primary lung cancer patients. Clin Cancer Res. 2008;14:2363–70.
Morini M, Astigiano S, Gitton Y, Emionite L, Mirisola V, Levi G, et al. Mutually exclusive expression of DLX2 and DLX5/6 is associated with the metastatic potential of the human breast cancer cell line MDA-MB-231. BMC Cancer. 2010;10:649.
Xu J, Testa JR. DLX5 (distal-less homeobox 5) promotes tumor cell proliferation by transcriptionally regulating MYC. J Biol Chem. 2009;284:20593–601.
Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C (T) method. Nat Protoc. 2008;3:1101–8.